Oxford Genetics secures £6.5m Series A funding from Mercia, Canaccord Genuity, and Invesco Asset Management
The financing values the synthetic biology business at £30.5m post-money.
Oxford Genetics provides advanced technologies and techniques for drug and gene therapy development. The company operates in the synthetic biology market, offering solutions for gene discovery, antibody therapy, and CRISPR gene editing.
Oxford Genetics has raised £6.5m in a Series A funding round from Mercia, Canaccord Genuity, and Invesco Asset Management. Mercia contributed £0.4m to the syndicate, bringing the post-money valuation of the business to £30.5m. The company develops technologies for drug and gene therapy development, building on patented DNA engineering methods. The fresh capital will support commercial growth and market expansion in sectors including CRISPR and antibody engineering.
From the founder
"This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering. Through our continued investment in automation and optimising our commercialisation strategy, we aim to maximise shareholder value and exceed our ambitious growth targets. Throughout our journey, Mercia’s investment model has been pivotal to Oxford Genetics’ current success. The ability to leverage capital and continued support from Mercia via seed stage through to later investment rounds has enabled us to attract excellent syndicate investors onto our share register. We are excited to welcome Canaccord Genuity onto our share register alongside Invesco Asset Management and look forward to working with all of our investors to grow the business over the coming years."
Ryan Cawood
Founder and CEO at Oxford Genetics
Investor perspective
"We have backed Oxford Genetics since day one, working closely with Ryan who has built both an impressive team and a highly scalable business model. Full year revenue to April 2019 is set to achieve c.300% growth on last year and the additional investment announced today will continue to facilitate this growth, as Oxford Genetics moves from an important domestic business to a global player in this specialist field of biotech."
Mark Payton
Chief Executive Officer, Mercia
Use of funds
- 01Continue product development
